PROSTAMAX

Part of Vladimir Khavinson's bioregulator peptide series developed in Russia, this compound specifically targets prostate tissue function. Research into Prostamax follows the Soviet-era tradition of organ-specific peptide therapy, though most investigation remains within Russian scientific circles with minimal Western validation.

The peptide appears to interact directly with prostate cell nuclei, influencing how genes are packaged and expressed within chromatin structures. In simple terms, it may help aging prostate cells maintain more youthful patterns of gene activity by affecting how tightly DNA is wound up in the cell nucleus, though the exact pathways remain unclear.